• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

Home > Press releases

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi
Monaco / Geneva — 8 Apr 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

From left to right: Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi

  • English
    • English
    • Français

The Government of the Principality of Monaco and the Drugs for Neglected Diseases initiative (DNDi) are pleased to announce their partnership to help put an end to the neglect of children living with HIV.

With a commitment of EUR 300,000 over three years (2022-2024), the Monegasque Cooperation for Development will support DNDi’s efforts to improve access to optimal HIV treatments for young children.

‘We are very pleased to count on the support of the Government of the Principality of Monaco,’ said Dr Bernard Pécoul, Executive Director of DNDi. ‘For too long, children living with HIV have been neglected, particularly those living in low-resource settings. Today, we are witnessing a revolution in the diagnosis and treatment of paediatric HIV. It is now our responsibility to ensure that children living with HIV have access to these game-changing diagnostics and treatments.’

Despite a huge increase in the number of adults accessing life-saving HIV treatment, children are still being left behind. Almost 800,000 kids living with HIV – the majority in sub-Saharan Africa – are not on treatment. This represents close to 50% of children living with HIV worldwide. Without treatment, half of all children born with HIV will die by the age of two.

South Africa has the largest HIV burden globally: with 310,000 children living with HIV, under half (47%) receive anti-retroviral treatment (ART). In Senegal, only a third of the 4,000 children living with HIV have access to ART.

This Monaco-funded project will work to address barriers to HIV treatment in these two countries. In South Africa, DNDi will support the registration of an improved taste-masked combination HIV treatment that is a marked improvement over the bitter-tasting and hard-to-administer options that are currently available in the country. In Senegal, the project will help strengthen local capacity to diagnose and treat HIV in children through training of healthcare personnel and local communities.

‘The Government of the Principality of Monaco is delighted with this partnership with DNDi to help improve access to treatment for children with HIV in two of its partner countries, South Africa and Senegal. This health partnership is in line with the priorities of the Monegasque Cooperation, with the most vulnerable as its main focus. We hope that advances in diagnosis and treatment for HIV will soon benefit the greatest number of children, so that no one is left behind’, said Bénédicte Schutz, Monaco’s Special Representative for International Cooperation.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in low- and middle-income countries. Since its inception in 2003, DNDi has delivered nine new treatments, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

About the Government of the Principality of Monaco

The Government of Monaco’s international development policy, which has made fight against poverty its priority, support around 150 projects each year in 11 countries, mainly LDCs (Madagascar, Mali, Burkina Faso, Niger, Mauritania, Senegal and Burundi). The aid focuses on four key areas of intervention to develop human capital – health, fod security, education & child protection, access to decent work – and targets the most vulnerable people (women, children, refugees, people with disabilities) as a priority. cooperation-monaco.gouv.mc

Media contacts 

DNDi – Frédéric Ojardias
fojardias@dndi.org
+41 79 431 62 16  

Government of the Principality of Monaco – Julien Siri
jsiri@gouv.mc
+377 98 98 49 76

Photo credit: Ariane Mawaffo-DNDi

Funding Paediatric HIV

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License